Our @atsblueeditor.bsky.social paper is online. We generated an age-adjusted nomogram for WGS-telomere length from #MESA & #COPDGene and applied it to IPF cases. doi.org/10.1093/ajrc...

Our paper is online @atsblueeditor.bsky.social examining gut microbiome features in IPF. We identified gut microbial signatures that correspond to lung function, survival, and interact with long-term antibiotic exposure. academic.oup.com/ajrccm/artic...

Recently sent this piece from @insight.jci.org on guide to K award applications for physician-scientists to a PCCM fellow: insight.jci.org/articles/vie... @atscommunity.bsky.social @ats-clinicalprobs.bsky.social

Finally in Print! The Official ATS Research Statement on Racial, Ethnic, Sex & Gender Equity for Inclusive Interstitial Lung Disease Research. 👏🏼 Drs Assayag, Adegonsoye, Cottin, Mageto & @atsblueeditor.bsky.social & @atscommunity.bsky.social #CurePF4All www.atsjournals.org/doi/10.1164/...

Okay #MedSky #AcademicSky 📚 What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM) Some journals invite 4-5 as default 🤯 I think 2 is sufficient, max 3 if controversy More reviewers ➡️ less AE provides input And SO many hours of free labour 💪

Thrilled our paper made it to the @atsblueeditor.bsky.social ILD issue this month. Look forward to building on this work and welcome collaboration with anyone interested in subclinical pulmonary fibrosis. I think a future research area is mapping the blood-lung proteome in this context.

The Blue Journal thanks Riley Hannan, PhD, for his contribution to the October issue Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities @jskim8223.bsky.social www.atsjournals.org/doi/full/10....

Our paper is online @atsblueeditor.bsky.social identifying plasma protein markers with HAA and correlating to new-onset fibrotic/subpleural ILA. Big thanks to our collaborators in #MESA & #SPIROMICS! www.atsjournals.org/doi/abs/10.1...

Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement @atscommunity.bsky.social #medsky 🔓 Open Access 🔗 tinyurl.com/4vjm9zdw

Current work playlist while writing. Any other music #PCCM are putting on in the background for work? @kaminskimed.bsky.social @kerrijohannson.bsky.social @ipfdoc.bsky.social @drdayjee.bsky.social @emilyfri.bsky.social @drpujamehta1.bsky.social? open.spotify.com/playlist/37i...

🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation 📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival 🔗 www.thelancet.com/journals/lan...

Delighted to share our new study evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with #PRS of IPF.

Had the privilege giving a talk about early ILD detection and sharing some of the research we are doing at #KATRD annual meeting in #Gyeongju. Thank you for the opportunity and meeting so many wonderful pulmonologists.

Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social www.nature.com/articles/s41...

Excited to post my first #skySplain about our recent work published yesterday in Nature Genetics! www.nature.com/articles/s41.... One of the first authors of this study - Annika Vannan – actually wrote this breakdown, but she's not yet over here on bluesky and asked me to post!

Genomic and Serological Rheumatoid Arthritis Biomarkers, MUC5B Promoter Variant, and Interstitial Lung Abnormalities @atscommunity.bsky.social #medsky 🔗 tinyurl.com/mr4cke25

🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟 Just out in @atsblueeditor.bsky.social 🫁 www.atsjournals.org/doi/abs/10.1... State of the Art: -Epidemiology -Mechanisms of Injury -Implications - clinical & policy -Future directions

Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we? @ipfdoc.bsky.social @kaminskimed.bsky.social #CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social pmc.ncbi.nlm.nih.gov/articles/pmi...

The Blue Journal thanks Catherine L. Debban, PhD, for her contribution to the December 15 issue Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan www.atsjournals.org/doi/full/10....

last night, Hallie Prescott had her NEJM review on sepsis released: www.nejm.org/doi/full/10.... Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan

Using Mendelian Randomisation to identify causal associations in #IPF a 🧵

For the new BlueSky members who have left #ILDTwitter I’ve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if I’ve missed you and I’ll add you 🫁😊 #CurePF #CureIPF #ILD go.bsky.app/8u4KcNo